HDAC9 and stroke disorder: Interestingly, unlike the non-selective HDAC inhibitors mentioned above, when the selective Class IIa HDAC inhibitor MC1568 was tested in vivo, it was found to increase mortality and lesion volume and impair neuronal remodeling after stroke; possibly through downregulation of phosphorylated cAMP response element-binding protein (CREB) and c-fos in neurons [24].